Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort

Monforte, AD; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; Vichi, F; Maddaloni, A; Lo Caputo, S; Gianotti, N; Antinori, A

Monforte, AD (reprint author), Univ Milan, Dept Hlth Sci, ASST Santi Paolo & Carlo, Clin Infect & Trop Dis, Milan, Italy.

HIV CLINICAL TRIALS, 2018; 19 (2): 52

Abstract

Background: We aimed to mimic the ACTG 5257 trial, comparing raltegravir (RAL), ritonavir-boosted atazavavir (ATV/r) and ritonavir-boosted darunavir (......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索